[1]仲斌演,滕皋军.中晚期肝细胞癌以TACE为基础的综合治疗[J].介入放射学杂志,2025,34(01):1-4.
　ZHONG Binyan,TENG Gaojun..TACE-based combination therapies in the management of intermediate-advanced stage hepatocellular carcinoma [J].journal interventional radiology,2025,34(01):1-4.
点击复制

中晚期肝细胞癌以TACE为基础的综合治疗()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年01
页码:
1-4
栏目:
述评
出版日期:
2025-01-22

文章信息/Info

Title:
TACE-based combination therapies in the management of intermediate-advanced stage hepatocellular carcinoma
作者:
仲斌演; 滕皋军
Author(s):
ZHONG Binyan; TENG Gaojun.
Department of Interventional Radiology，First Affiliated Hospital of Soochow University，Suzhou，Jiangsu Province 215006，China；Center of Interventional and Vascular Surgery，Department of Radiology,Zhongda Hospital,Medical School Southeast University，Nanjing，Jiangsu Province 210009，China
关键词:
【关键词】肝细胞癌; 经动脉化疗栓塞; 免疫治疗; 系统治疗
文献标志码:
A
摘要:
仲斌演，滕皋军【摘要】经动脉化疗栓塞（TACE）在中晚期肝细胞癌（HCC）的治疗中发挥着重要作用。基于TACE术后肿瘤内部缺氧环境导致血管内皮生长因子增加，使TACE术后病灶进展风险增加这一情况，TACE联合抗血管生成药物治疗中晚期HCC理论上可起到协同增效作用。然而，这方面的研究大多以失败告终。近年来，免疫治疗在HCC领域取得的进展突破，这既推动了TACE治疗，也面临着全身系统治疗的新挑战。考虑到两者间潜在的协同作用机制，TACE联合免疫治疗为主的系统治疗可能比单一治疗更能提高对中晚期HCC患者的疗效。该文结合以TACE为基础的综合治疗这一领域现有的研究证据，讨论已发表和正在进行的研究中关于TACE联合治疗的证据，探讨基于TACE的综合治疗在中晚期HCC患者治疗中的协同疗效及重要地位。

参考文献/References:

［1］Bray F，Laversanne M，Sung H，et al.Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2024，74：229-263.
［2］Llovet JM，Kelley RK，Villanueva A，et al.Hepatocellular carcinoma［J］.Nat Rev Dis Primers，2021，7：6.
［3］Reig M，Forner A，Rimola J，et al.BCLC strategy for prognosis prediction and treatment recommendation：the 2022 update［J］.J Hepatol，2022，76：681-693.
［4］Park J，Chen M，Colombo M，et al.Global patterns of hepatocellular carcinoma management from diagnosis to death：the BRIDGE Study［J］.Liver Int，2015，35：2155-2166.
［5］刘嵘，程永德，王小林，等.中国肝细胞癌TACE治疗的历史、现状和展望——纪念我国介入放射学奠基人林贵教授［J］.介入放射学杂志，2022，31：743-746.
［6］Llovet JM，Real MI，Montana X，et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma：a randomised controlled trial［J］.Lancet，2002，359：1734-1739.
［7］Lo CM，Ngan H，Tso WK，et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma［J］.Hepatology，2002，35：1164-1171.
［8］Lencioni R，de Baere T，Soulen MC，et al.Lipiodol transarterial chemoembolization for hepatocellular carcinoma：a systematic review of efficacy and safety data［J］.Hepatology，2016，64：106-116.
［9］Zhong BY，Jin ZC，Chen JJ，et al.Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma［J］.J Clin Transl Hepatol，2023，11：480-489.
［10］中国医师协会介入医师分会临床诊疗指南专委会.肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识［J］.介入放射学杂志，2022，31：1039-1044.
［11］Zhang L，Sun JH，Ji JS，et al.Imaging changes and clinical complications after drug-eluting bead versus conventional transarterial chemoembolization for unresectable hepatocellular carcinoma：multicenter study［J］.AJR Am J Roentgenol，2021，217：933-943.
［12］Deng G，Zhao DL，Li GC，et al.Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor［J］.Cardiovasc Intervent Radiol，2011，34：824-832.
［13］Kudo M，Ueshima K，Ikeda M，et al.Final results of TACTICS：A randomized，prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma［J］.Liver Cancer，2022，11：354-367.
［14］Peng Z，Fan W，Zhu B，et al.Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma：a phase Ⅲ，randomized clinical trial （LAUNCH）［J］.J Clin Oncol，2023，41：117-127.
［15］Finn RS，Qin SK，Ikeda M，et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］.N Engl J Med，2020，382：1894-1905.
［16］Ren Z，Xu J，Bai Y，et al.Sintilimab plus a bevacizumab biosimilar （IBI305） versus sorafenib in unresectable hepatocellular carcinoma （ORIENT-32）：a randomised，open-label，phase 2-3 study［J］.Lancet Oncol，2021，22：977-990.
［17］Qin S，Chan S，Gu S，et al.Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma （CARES-310）：a randomised，open-label，international phase 3 study［J］.Lancet，2023，402：1133-1146.
［18］Zhu HD，Li HL，Huang MS，et al.Transarterial chemoembolization with PD-（L）1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma （CHANCE001）［J］.Signal Transduct Target Ther，2023，8：58.
［19］Jin ZC，Zhong BY，Chen JJ，et al.Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC （CHANCE2211）：a propensity score matching study［J］.Eur Radiol，2023，33：8669-8681.
［20］Jin ZC，Chen JJ，Zhu XL，et al.Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma （CHANCE2201）：a target trial emulation study［J］.E Clinical Medicine，2024，72：102622.
［21］LEncioni R，Kudo M，Erinjeri J，et al.EMERALD-1：a phase 3，randomized，placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization［J］.J Clin Oncol，2024，42：LBA432.

相似文献/References:

[1]李晓光,金征宇,杨宁,等.经动脉灌注化疗或栓塞治疗恶性胰岛素瘤肝转移[J].介入放射学杂志,2008,(11):803.
　LI Xiaoguang,JIN Zhengyu,YANG Ning,et al.Transcatheter arterial chemoperfusion or chemoembolizaiton for treatment of liver metastasis from malignant insulinoma[J].journal interventional radiology,2008,(01):803.
[2]姚志敏,佟小强,宋莉,等.宫颈癌术前动脉化疗栓塞疗效[J].介入放射学杂志,2009,(03):189.
　YAO Zhimin,TONG Xiaoqiang,SONG Li,et al.Preoperative transarterial chemoembolization for cervical cancer：analysis of efficacy[J].journal interventional radiology,2009,(01):189.
[3]张琳,牟玮,王健,等.乙酸化学消融联合肝动脉化疗栓塞治疗肝脏恶性肿瘤[J].介入放射学杂志,2007,(12):831.
　ZHANG Lin,MU Wei,WANG Jian,et al.CT fluoroscopic guidance percutaneous acetic acid injection tumor ablation and TACE for the malignant liver tumor[J].journal interventional radiology,2007,(01):831.
[4]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(01):543.
[5]王惠文,刘瑞宝,李晓婧,等.载药微球-TACE治疗难治性妇科恶性肿瘤肝转移12例[J].介入放射学杂志,2021,30(06):568.
　WANG Huiwen,LIU Ruibao,LI Xiaojing,et al.Drug- eluting beads - TACE for the treatment of refractory liver metastases from synecological malignant tumors： preliminary results in 12 patients[J].journal interventional radiology,2021,30(01):568.
[6]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(01):55.
[7]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(01):36.
[8]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(01):90.
[9]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):921.
[10]石佳鹏,汤小星,顾祝新,等.TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究[J].介入放射学杂志,2024,33(09):995.
　SHI Jiapeng,TANG Xiaoxing,GU Zhuxin,et al.TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study[J].journal interventional radiology,2024,33(01):995.
[11]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):968.

备注/Memo

备注/Memo:
（收稿日期：2024-09-20）
（本文编辑：新宇）
更新日期/Last Update: 2025-01-22